Manulife (Manufacturers Life Insurance)
CTMX icon

Manulife (Manufacturers Life Insurance)’s CytomX Therapeutics CTMX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,027
Closed -$80.2K – 3038
2022
Q1 		$80.2K Sell
30,027
-6,323
-17% -$24.3K ﹤0.01% 2991
2021
Q4 		$157 Sell
36,350
-1,682
-4% -$9.85K ﹤0.01% 2975
2021
Q3 		$194K Sell
38,032
-1,249
-3% -$6.69K ﹤0.01% 2998
2021
Q2 		$249K Buy
39,281
+1,860
+5% +$14.5K ﹤0.01% 2950
2021
Q1 		$289K Buy
37,421
+7,346
+24% +$58.1K ﹤0.01% 2641
2020
Q4 		$197K Buy
30,075
+2,449
+9% +$17.5K ﹤0.01% 2786
2020
Q3 		$184K Hold
27,626
– – ﹤0.01% 2600
2020
Q2 		$227K Sell
27,626
-2,351
-8% -$21.8K ﹤0.01% 2431
2020
Q1 		$230K Buy
29,977
+1,421
+5% +$9.91K ﹤0.01% 2239
2019
Q4 		$237K Sell
28,556
-558
-2% -$3.77K ﹤0.01% 2479
2019
Q3 		$224K Hold
29,114
– – ﹤0.01% 2513
2019
Q2 		$327K Sell
29,114
-843
-3% -$8.84K ﹤0.01% 2311
2019
Q1 		$322K Buy
29,957
+2,440
+9% +$36.1K ﹤0.01% 2242
2018
Q4 		$416K Sell
27,517
-1,819
-6% -$27K ﹤0.01% 2072
2018
Q3 		$543K Buy
29,336
+251
+0.9% +$5.72K ﹤0.01% 2233
2018
Q2 		$666K Buy
29,085
+7,164
+33% +$183K ﹤0.01% 2167
2018
Q1 		$624K Sell
21,921
-705
-3% -$20.1K ﹤0.01% 2173
2017
Q4 		$477K Sell
22,626
-381
-2% -$7.9K ﹤0.01% 2352
2017
Q3 		$418K Sell
23,007
-522
-2% -$8.14K ﹤0.01% 2398
2017
Q2 		$365K Buy
23,529
+6,342
+37% +$95.6K ﹤0.01% 2530
2017
Q1 		$296K Buy
17,187
+1,768
+11% +$23.3K ﹤0.01% 2552
2016
Q4 		$169K Sell
15,419
-25
-0.2% -$303 ﹤0.01% 2916
2016
Q3 		$242K Sell
15,444
-302
-2% -$3.65K ﹤0.01% 2626
2016
Q2 		$161K Buy
15,746
+9,946
+171% +$113K ﹤0.01% 2886
2016
Q1 		$74K Buy
+5,800
New +$80.5K ﹤0.01% 3174

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s CTMX Position: Q2 2022 in Review

Manulife (Manufacturers Life Insurance) sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 30,027 shares — an estimated $80.2K sold.

Manulife (Manufacturers Life Insurance) first reported a position in CTMX in Q1 2016 and held it in 25 quarters. The position peaked at $666K in Q2 2018. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Manulife (Manufacturers Life Insurance) reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 30,027 CytomX Therapeutics shares in Q2 2022, an estimated $80.2K.
  • Manulife (Manufacturers Life Insurance) first reported a position in CytomX Therapeutics in Q1 2016 and held it in 25 quarters.
  • Manulife (Manufacturers Life Insurance)'s CytomX Therapeutics position peaked at $666K in Q2 2018.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2022, filed 15 Aug 2022.